Johnson and Johnson

Johnson and Johnson is a multinational company that has around 250 companies located in more than 60 countries around the world. It has three major business segments that include Consumer Healthcare, Medical Devices and Diagnostics and Pharmaceuticals.

JNJ’s revenues have been growing for the past 3 years with 2013 revenues announced at $71.3 billion. The EPS has been increasing as well with

EPS for 2013 announced at $5.52. Annually, EPS are expected to grow 5.33%. JNJ Net sales are also appreciating around 4% annually. 2013 sales were announced at $71.3 billion

Johnson and Johnson stock price today as of 26^th March is trading at $97.38 up 2.29% from last night’s closing price of $95.2. Johnson and Johnson stock has appreciated 6% since the start of 2014 and is expected to appreciate to $102 in the upcoming 12 months.

Johnson and Johnsonstock price has appreciated 21% since 26^th March, 2013. The company’s stock had recently hit a 52 week high and investors are buying the shares as if there is no tomorrow.

At a time when many drug companies are finding it hard to add new revenue sources as their patents are expiring, JNJ has continued to grow its revenues and Earnings year over year (YoY).

JNJ stock price is still not as expensive and is rated as a buy by majority analysts.